Do any medical organizations endorse miRNA-based cancer screening?

As of 2025, no major medical organization (ACS, USPSTF, ASCO) has issued formal guidelines endorsing any multi-cancer early detection (MCED) test for routine population screening — including Galleri, Shield, or OncuraKit. All MCED tests, including OncuraKit, are in the evidence-building phase. OncuraKit is a Laboratory Developed Test (LDT) operating under CLIA certification. The American Cancer Society and USPSTF typically require large prospective clinical trials (like the GRAIL NHS study in the UK) demonstrating mortality reduction before issuing endorsements. The Yenos platform has four published peer-reviewed studies supporting its accuracy, and the platform is available for use by individuals and healthcare organizations who want proactive access to this science ahead of formal guideline development.